“The existing situation has uncovered some structural weaknesses during the EU’s medicines offer chain and also a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides reported. She proposed that offer chain concerns be addressed within an EU pharmaceutical st